Proactive Investors - Run By Investors For Investors

Breakfast News - AIM Breakfast : Allergy Therapeutics plc, Connemara Mining, Empyrean Energy Plc., Keywords Studios PLC, LightwaveRF, MySQUAR Limited, Oxford Metrics, Sareum Holdings Plc, StatPro Group PLC, Tristel Plc

Breakfast News - AIM Breakfast :  Allergy Therapeutics plc, Connemara Mining, Empyrean Energy Plc., Keywords Studios PLC, LightwaveRF, MySQUAR Limited, Oxford Metrics, Sareum Holdings Plc, StatPro Group PLC, Tristel Plc

What’s cooking in the IPO kitchen?


Novacyt S.A.—Sch1 from the international diagnostics group, generating revenues from the sale of clinical products used in oncology, microbiology, haematology and serology testing. Offer to raise £8.8m at 59.38p with a value of £22.4m. Expected 01 Nov.

Footasylum Ltd—UK-based fashion retailer focusing on the branded footwear and apparel markets announced its intention to seek admission to AIM. Expected value between £130m and £150m. Due Nov 2017.

Totally (TLY) - Sch 1 for £11m RTO of Vocare,  a provider of integrated urgent care services to the NHS throughout the UK. £76.8 million rev in the year ended 31 March 2017. Totally to address Care Quality Commission concerns. Due 24 Oct.

Central Asia Metals (CAML) -RTO of Lynx Resources. Anticipated market capitalisation at Admission: £404.8m. Raising £113m at 230p. Acquiring the SASA zinc-lead mine in Macedonia from Solway Industries. Due 15 Dec. 

Breakfast buffet

Sareum Holdings* (LON:SAR) 0.95p £27.77m

The specialist cancer drug discovery and development company, announced its final results for the year ended 30 June 2017.

· Lead cancer drug candidate SRA737, a novel Chk1 inhibitor, licensed for clinical development and commercialisation to NASDAQ-listed company Sierra Oncology, Inc. by Sareum's co-investment partner, CRT Pioneer Fund

· Sareum is eligible to receive 27.5% of up to $328.5m in upfront, development and commercialisation milestone payments as well as royalties on sales.

· An upfront payment of $7m and a first milestone payment of $2m have already been received from Sierra Oncology

· Patents protecting SRA737 were granted in the USA and Europe, extending the protection period to 2033 in the USA.

· Successful outcome from feasibility study with TYK2 inhibitors in T-Cell Acute Lymphoblastic Leukaemia. In disease models, Sareum's compounds demonstrated good oral bioavailability, were well tolerated and showed tumour reduction of up to 80%.

· Further patent grants for Aurora+FLT3 kinase programme in Japan, Singapore, China, and Hong Kong.

· Maiden profit on ordinary activities of £0.4m (2016: loss of £1.05m).

· Net assets at period end were £2.34m (2016: £1.86m), of which £2.31m comprised cash at bank (2016: £1.25m).

Allergy Therapeutics (LON:AGY) 37.5p £222m

The fully integrated specialty pharmaceutical group specialising in allergy vaccines, announced that dosing has commenced in its G205 Phase II study designed to evaluate the dose-response and safety of its ultra-short course, aluminium free PQ Grass immunotherapy to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.

The study is anticipated to run for one year and involve approximately 440 patients in more than 50 sites across Germany, Austria and Poland.  The trial is designed to identify the optimal efficacious cumulative dose using conjunctival provocation testing. This type of challenge testing has recently been used in studies for a similar subcutaneous birch pollen product resulting in selection and approval of dose for use in a current phase III study. The results of the G205 trial are expected in H2 2018. Following completion of this trial, meetings with the regulatory authorities in the US and Germany will be necessary to enable Phase III trial design.

Empyrean Energy (LON:EME) 22.25p £88.28m

The oil and gas development company with interests in China, Indonesia and the United States, announced that it has been informed by Sacgasco Limited, the operator of the Dempsey 1-15 well in the Sacramento Basin, onshore California, that Paul Graham Drilling Rig 3 and associated equipment has moved onto the Dempsey 1-15 well location to carry out the planned and previously announced completion and testing program.

On the way to the Dempsey site the rig undertook a successful re-completion of one of the adjacent JV-owned producing wells at the Rancho Capay Gas Field.

"Empyrean is delighted that most of the preparations are now complete and that testing at the Dempsey 1-15 well is to commence shortly.  There were multiple interesting zones that gave gas shows whilst drilling.  The deepest of these zones will be tested first and we look forward to providing further updates as the testing program unfolds."

MySQUAR (LON:MYSQ) 2.18p £12.47m

The Myanmar-language social media, entertainment and payments platform whose principal activity is to design, develop and commercialise Myanmar-focused internet-based mobile applications, announced it has signed a Memorandum of Understanding to enter into a partnership with other service providers for the financing and delivery of Wi-Fi services and digital content on the Myanmar Railways.  Digital content such as video games and chat platforms, advertisements and internet access are also included.

Revenue is anticipated to be generated from advertising and from telecoms through direct carrier billing from video games and streaming content.  There will be a revenue share agreement between the Partnership and Myanmar Railways, which will be net of all operating and administrative fees necessary for the deployment of this network.

StatPro Group (LON:SOG) 151p £97.72m

The cloud-based portfolio analysis and asset pricing services provider for the global asset management industry, provides a trading update for the nine months ended 30 September 2017.

Revenue and profits continue to be in line with the Board's expectations for the current year.

In the 12 months to 30 September 2017, Group Annualised Recurring Revenue ("ARR"), increased by 40% to £52.9m(September 2016: £37.9m at constant currency), which includes the addition of ARR for Delta, the cloud-based risk and performance analytics service, acquired in May 2017.

The percentage of Group ARR that is Software as a Service has continued to increase to 83% (September 2016: 75% at constant currency).

Keywords Studios (LON:KWS) 1,381p £773.08m

The international technical services provider to the global video games industry, announced that it has acquired d3t ltd, for a total consideration of £3m from the founders.

Based in the North West of England, between Liverpool and Manchester, d3t delivers premium quality outsourced software development services for video game developers and publishers internationally.

The acquisition of d3t is in line with Keywords Studios' strategy to grow organically and by acquisition as it selectively consolidates the highly fragmented market for video game services.  d3t brings additional skills, client relationships and geographic reach to Keywords, extending the strength and scale of its recently established Engineering service line.

LightwaveRF (LON:LWRF) 19.25p £7.17m

The leading smart home solutions provider, announced that its next generation Apple HomeKit certified product range, for controlling smart devices with iOS apps and Siri voice commands, is now available to purchase via the Apple Online Store. The new range is expected to be placed on the display shelves of Apple UK stores next month and orders placed online can be collected in selected stores from now.

"It's fantastic to confirm that our Apple HomeKit certified products are now available via the Apple Online Store. With the Apple Home app, users can easily and securely control all Lightwave accessories.  This is a major new route to market for us and we are looking forward to extending our relationship with Apple as they expand the HomeKit programme."

Oxford Metrics (LON:OMG) 60.50p £72.29m

The international software company servicing government, life sciences, entertainment and engineering markets, provided the following update on trading for the financial year ended 30 September 2017.

The Group enjoyed a successful close to the financial year and expects to report both revenues and adjusted PBT slightly ahead of market expectations.

The Board is pleased to report the Group has made good progress during this first year of the Group's five-year growth plan and is on track to achieve the goals we stated in December 2016 to double profits and triple recurring revenue by 2021.

The cash balance for the year closed at £9.8m (FY16: £8.3m).

Tristel (LON:TSTL) 287.5p £126.07m

The manufacturer of infection prevention and contamination control products, announced the appointment of Tom Jenkins to the Board as a non-executive director.

Tom qualified as a chartered accountant with Arthur Anderson in 1998 and has 16 years' experience supporting ambitious growing businesses. He worked in corporate finance at Dresdner Kleinwort Benson and Bear Stearns before moving into broking, where for six years he was head of equity capital markets at finnCap and a board member. In 2015, he joined BGF as an investor in their quoted team.

"We are delighted to welcome Tom to the Board. He brings a wealth of public company experience which will be invaluable in helping us achieve our ambitions. We very much look forward to working with him."

Connemara (LON:CON) 3.72p £2.79m

The Company announced the acquisition of 100% of Hendrick Resources ("HRI").  Connemara has acquired 100% control of 12 existing HRI prospecting licences in Ireland for a royalty agreement comprising a 2%. Net Smelter Return on future production.  In addition, the 5 Connemara prospecting licences in joint venture with HRI have been returned to Connemara. Though the primary focus is gold, lithium pegmatite targets are being developed adjacent to the western margin of the block and Connemara is reviewing potential targets within the expanded block.

"We are pleased to acquire HRI, a company created by the late Dale Hendrick, a legendary figure in gold exploration.  All 17 licences acquired are focused on the gold in the Wicklow/ Wexford area.  The acquisition has increased the strike length of the primary gold target in Wicklow from around 5kms to 15kms.”

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use